✦ LIBER ✦

Re-treatment of chronic hepatitis C with consensus interferon

✍ Scribed by E. Jenny Heathcote; Emmet B. Keeffe; Samuel S. Lee; Saya V. Feinman; Myron J. Tong; K. R. Reddy; Karsten Witt; Lawrence M. Blatt

Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 106 KB
Volume: 27
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.510270431

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re-treatment with interferon alfa of pat

Re-treatment with interferon alfa of patients with chronic hepatitis C

✍ Wan-Cheng Chow; Nathalie Boyer; Michele Pouteau; Corinne Castelnau; Michele Mart 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

Treatment of patients with chronic hepatitis C has had limited success because of relapses and nonresponse to interferon alfa therapy (currently the only established therapeutic agent). A retrospective study was done to determine the efficacy of re-treatment with interferon and the predictors of res

Treatment of chronic hepatitis C with co

Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial

✍ M J Tong; K R Reddy; W M Lee; P J Pockros; J C Hoefs; E B Keeffe; F B Hollinger; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 1 views

AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC

Chronic hepatitis C virus patients with

Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon

✍ E. Jenny Heathcote; Stephen James; Kevin D. Mullen; S. C. Hauser; H. Rosenblate; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

Patients with chronic hepatitis C who have not had a sustained hepatitis C virus (HCV)-RNA response or serum alanine transaminase (ALT) response to a 6-month course of interferon (IFN) may respond to higher dose retreatment with consensus interferon (CIFN). Some nonresponders to initial IFN treatmen

Therapy of hepatitis C: Re-treatment wit

Therapy of hepatitis C: Re-treatment with alpha interferon

✍ A Alberti; L Chemello; F Noventa; L Cavalletto; GianLuca De Salvo 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

The long-term benefit of interferon therapy in chronic hepatitis C is limited. During therapy, serum alanine aminotransferase (ALT) levels decrease to normal and hepatitis C virus (HCV) RNA decreases in 40% to 60% of patients. However, most patients relapse after therapy withdrawal, so that no more

Therapy of hepatitis C: Consensus interf

Therapy of hepatitis C: Consensus interferon trials

✍ E B Keeffe; F B Hollinger 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 1 views

Chronic hepatitis C is an insidious disease associated with prior interferon therapy were more likely to have a serum HCV RNA end-of-retreatment and sustained response than significant morbidity and mortality. Currently, the only approved therapies for chronic hepatitis C are the alpha interfer-pati

Treatment of children with chronic hepat

Treatment of children with chronic hepatitis C with recombinant interferon-α: A pilot study

✍ Mercedes Ruiz-Moreno; Maria José Rua; Inmaculada Castillo; Maria Dolores García- 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Twelve children with chronic non-A, non-B hepatitis were entered in a pilot trial of recombinant interferon-alpha. Although all the children had hepatitis C virus RNA in serum, only five had antibodies against this virus. Children received 3 MU/m2 body surface area interferon-alpha 3 times/wk for 6